Why the study?
General endotracheal anesthesia has historically been the primary sedation method during TAVR, but conscious sedation has emerged as a safe option and comparative data between the two modalities remain limited.
Does conscious sedation reduce hospital length of stay, ICU length of stay, and adverse events compared to general anesthesia in patients undergoing TAVR?
Does conscious sedation reduce hospital length of stay, ICU length of stay, and adverse events compared to general anesthesia in patients undergoing TAVR?
Conscious sedation during TAVR is associated with shorter hospital and ICU lengths of stay without an increased risk of adverse events compared to general anesthesia.
CS may be feasible for TAVR; leaves open whether randomized trials confirm safety versus GETA.
Introduction: Transcatheter Aortic Valve Replacement (TAVR) has been established as a viable alternative to surgical aortic valve replacement (SAVR) when treating symptomatic aortic stenosis in intermediate and high risk patients. Historically, general endotracheal anesthesia (GETA) has been the primary form of patient sedation during TAVR. Recently, conscious sedation (CS) has been utilized as a safe option. As there are limited data available comparing these two modalities, it would be helpful to investigate this question further. Methods: To determine the potential benefits of using conscious sedation compared to general anesthesia, 3 outcomes were compared in patients experiencing each method: (1) Total hospital length of stay (LOS), (2) ICU LOS, and (3) occurrence of adverse events (AEs) during hospitalization. Results: Hospital LOS and ICU LOS were found to have a correlation with anesthesia method. CS was correlated with shorter hospital and ICU stays compared to GETA. There were no significant differences between CS and GETA in terms of occurrence of AEs, indicating that the risk of complications was similar for both anesthesia methods. Conclusion: Conscious sedation compared to general anesthesia could potentially be the better alternative for TAVR with no increased adverse events.
No takes yet. Share an insight, caveat, or question.
Bhandari et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: